Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Boston, Massachusetts-- (Newsfile Corp. - January 15, 2025) - Berman Tabacco announces that it is investigating potential securities law violations by TransMedics Group, Inc. ("TransMedics" or the ...

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company’s alleged misconduct poses an existential threat. Hagens Berman’s ...

SAN FRANCISCO, Jan. 14, 2025 /PRNewswire/ -- Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by ...